ID	Database	Citation
10608481	Pubmed	"Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro. Wang JS, Backman JT, Wen X, Taavitsainen P, Neuvonen PJ, Kivistö KT. Pharmacol Toxicol. 1999 Nov;85(5):201–5.  <a href=""http://www.ncbi.nlm.nih.gov/pubmed/10608481"" target=""_blank"" class=""external"" rel=""nofollow"">PubMed</a> <a href=""https://europepmc.org/abstract/MED/10608481"" target=""_blank"" class=""external"" rel=""nofollow"">Europe PMC</a> <a href=""https://scholia.toolforge.org/pubmed/10608481"" target=""_blank"" class=""external"" rel=""nofollow"">Scholia</a>"
14749694	Pubmed	"Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, Palatini P. Clin Pharmacol Ther. 2004 Jan;75(1):80–8.  <a href=""http://www.ncbi.nlm.nih.gov/pubmed/14749694"" target=""_blank"" class=""external"" rel=""nofollow"">PubMed</a> <a href=""https://europepmc.org/abstract/MED/14749694"" target=""_blank"" class=""external"" rel=""nofollow"">Europe PMC</a> <a href=""https://scholia.toolforge.org/pubmed/14749694"" target=""_blank"" class=""external"" rel=""nofollow"">Scholia</a>"
16918719	Pubmed	"Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine. Isohanni MH, Neuvonen PJ, Olkkola KT. Basic Clin Pharmacol Toxicol. 2006 Aug;99(2):168–72.  <a href=""http://www.ncbi.nlm.nih.gov/pubmed/16918719"" target=""_blank"" class=""external"" rel=""nofollow"">PubMed</a> <a href=""https://europepmc.org/abstract/MED/16918719"" target=""_blank"" class=""external"" rel=""nofollow"">Europe PMC</a> <a href=""https://scholia.toolforge.org/pubmed/16918719"" target=""_blank"" class=""external"" rel=""nofollow"">Scholia</a>"
